BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Soler LM, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22:678-89. [PMID: 33848462 DOI: 10.1016/S1470-2045(21)00145-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Shan W, Wu G, Huang Y, Zeng H, Xia W, Lin Z, Xu B. Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. Ann Hematol 2022;101:1741-53. [PMID: 35688904 DOI: 10.1007/s00277-022-04876-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Matasar MJ, Hiemeyer F, Childs BH, Zinzani PL. PI3K inhibitors in haematological malignancies. The Lancet Oncology 2022;23:e365. [DOI: 10.1016/s1470-2045(22)00332-1] [Reference Citation Analysis]
3 Shouse G, Danilova OV, Danilov AV. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. Curr Opin Oncol 2022. [PMID: 35855508 DOI: 10.1097/CCO.0000000000000871] [Reference Citation Analysis]
4 Forero-Torres A, Chandler JC, Iyer SP, Kanate AS, Quinlan M, Hoever P, Izquierdo M, Davis J, Madan S. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma. Clin Pharmacol Drug Dev 2022. [PMID: 35819310 DOI: 10.1002/cpdd.1133] [Reference Citation Analysis]
5 Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00200-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Liu W, Ping L, Xie Y, Sun Y, Du T, Niu Y, Cisternas G, Huang F, Garcia-Vargas J, Childs BH, Mehra A, Reschke S, Wang X, Song Y, Zhu J. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2022. [PMID: 35322287 DOI: 10.1007/s00280-022-04417-3] [Reference Citation Analysis]
7 Tang X, Chen X, Zhang T, Jiang J. Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis. Ann Transl Med 2022;10:352. [PMID: 35433977 DOI: 10.21037/atm-22-1159] [Reference Citation Analysis]
8 Raychaudhuri R, Ujjani C. Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat. OTT 2022;Volume 15:193-9. [DOI: 10.2147/ott.s267011] [Reference Citation Analysis]
9 Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, Béguelin W, Zappasodi R. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Front Cell Dev Biol 2021;9:805195. [PMID: 35071240 DOI: 10.3389/fcell.2021.805195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang B, Li X, Yin T, Qin D, Chen Y, Ma Q, Shu P, Wang Y, Marchetti C. Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/4259205] [Reference Citation Analysis]
11 Qualls D, Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 2022;107:19-34. [PMID: 34985231 DOI: 10.3324/haematol.2021.278717] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Leslie LA. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas. Curr Treat Options Oncol 2021;22:111. [PMID: 34694508 DOI: 10.1007/s11864-021-00909-1] [Reference Citation Analysis]
13 Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol 2021;14:127. [PMID: 34407844 DOI: 10.1186/s13045-021-01132-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pongas G, Cheson B. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. Blood Lymphat Cancer 2021;11:55-66. [PMID: 34354386 DOI: 10.2147/BLCTT.S267569] [Reference Citation Analysis]